1) Scandinavian Simvastatin Survival Study
Group. Randomized trial of cholesterol lowering in 4444 patients with
coronary heart disease. Lancet 1994;344:1383-9.
2) Shepherd J,et al.Prevention of coronary heart disease
with pravastatin in men with hypercholesterolemia.N Engl J Med 1995;333:1301-7.
3) Sacks FM,et al.The effect of pravastatin on coronary
events after myocardial infarction on patients with average cholesterol
levels. N Engl J Med 1996;335:1001-9.
4) The Long term Intervention with Pravastatin in Ischaemic
Disease Study Group.Prevention of cardiovasculsr events and death with
pravastatin in patients with coronary heart disease and a broad range
of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
5) Down JR,et al.Primary prevention of acute coronary
events with lovastatin in men and women with average cholesterol levels:
results of AFCAPS/TexCAPS. JAMA 1998;279:1615-22.
6) Blankenhorn DH,et al.Coronary angiographic change
with lovastatin therapy. Ann Intern Med 1993;119:969-76.
7) MAAS Investigators.Effect of simvastatin on coronary
atheroma: the Multicentre Anti Atheroma Study.Lancet 1994;344:633-8.
8) Pitt B, et al.Design and recruitment in the United
States of a multicenter quantitative angiographic trial of pravastatin
two limit atherosclerosis in the coronary arteries.J Am Coll Cardiol
1995;26:1133-9.
9) Jukema JW, et al.Effects of lipid lowering by pravastatin
on progression and regression of coronary artery disease in symptomatic
men with normal to moderately elevated serum cholesterol levels. Circulation
1995;91:2528-40.
10) Pitt B, et al.Aggressive lipid lowering therapy
compared with angioplasty in stable coronary artery disease. N Engl
J Med 1999;341:70-6.
11) MIRACL Study Invvestigators.Effect of atorvastatin
on early recurrent ischemic events in acute coronary syndrome. JAMA
2001;285(13):1711-8.
12) Thompson PL, et al. Clinical relevance of statins:
instituting treatment early in acute coronary syndrome patients. Atheroscler
suppl 2001;2:15-9.
13) Kannel WB, et al. Serum cholesterol, lipoprotein
and risk of coronary heart disease. The Framingham study. Ann Intern
Med 1971;74:1-12.
14) The Scandinavian Simvastatin Survival Study Group.
Cholesterol lowering therapy in women and elderly patients with myocardial
infarction or angina pectoris. Circulation 1997; 96:4211-8.
15) The Scandinavian Simvastatin Survival Study Group.
Cholesterol lowering with simvastatin improves prognosis of diabetic
patients with coronary heart disease. A subgroup analysis of the Scandinavian
Simvastatin Survival Study. Diabetes Care 1997;20(4):614-20.
16) The CARE Investigators.Cardiovascular events and
their reduction with pravastatin in diabetic and glucose intolerant
myocardial infarction survivors with average cholesterol levels. Subgroup
analysis in the Cholesterol And Recurrent Event(CARE) Trial.Circulation
1998; 98:2513-9.
17) The CARE Investigators.Effect of pravastatin on
cardiovascular events in older patients with myocardial infarction and
cholesterol level in the average range. Results of the Cholesterol And
Recurrent Event(CARE) Trial. Ann Intern Med 1998;129(9):681-9.
18) The LIPID Investigators. Benefits of pravastatin
on cardiovascular events and mortality in older patients with coronary
heart disease are equal to or exceed those seen in younger patient:
result from the LIPID Trial. Ann Intern Med 2001;134(10):931-40.
19) Butcher HC, et al.Effect of HMGcoA reductase inhibitors
on stroke. Ann Intern Med 1998; 128 : 89-95.
20) Steering Committee of the Physicians' Health Study
Research Group. Final report on the aspirin component of the ongoing
Physicians' Health Study. N Engl J Med 1989;321:129-35.
21) Peto R, et al. Randomised trial of prophylactic
daily aspirin in British male doctors.Br Med J 1988;296:313-6.
22) HOT Study Group.Effect of intensive blood pressure
lowering and low dose aspirin in patients with hypertension: principle
results of the Hypertension Optimal Treatment randomized trial. Lancet
1998;351:1755-62.
23) ISIS-2 Collaboration Group.Randomized trial of intravenous
streptokinase, oral aspirin, both or neither among 17,187 cases of suspected
acute myocardial infarction: ISIS─2.Lancet 1998;2:349-60.
24) Kleiman NS,et al. Profound inhibition of platelet
aggregation with monoclonal antibody 7E3 after thrombolytic therapy.
Results of the Thrombolysis and Angioplasty in Myocardial Infarction
8 pilot study. J Am Coll Cardiol 1993;22:381-9.
25) Antman EM, et al. Abciximab facilitates the rate
and extent of thrombolysis:results of the thrombolysis in myocardial
infarction 14 trial. The TAMI 14 Investigators. Circulation 1999;99(21):2720-32.
26) Ohman EM,et al. Combined accelerated tissue plasminogen
activator and platelet glycoprotein IIb/IIIa integrin receptor blockade
with integrilin in acute myocardial infarction. Results of a randomized,
placebo controlled, dose ranging trial. IMPACT─AMI Investigators. Circulation
1997;95(4):846-54.
27) Lewis HD,et al. Protective effect of aspirin against
acute myocardial infarction and death in men with unstable angina. N
Engl J Med 1983;309:396-403.
28) The CAPTURE Investigators.Randomized placebo controlled
trials of abciximab before and during coronary interventions in refractory
unstable angina: the CAPTURE study. Lancet 1997;349:1429-35.
29) Boersma E,et al. Platelet glycoprotein IIb/IIIa
receptor inhibition in non ST elevation acute coronary syndromes: early
benefit during medical treatment only, with additional protection during
percutaneous coronary intervention. Circulation 1999;100(20):2045-8.
30) Zhao XQ, et al. Intracoronary thrombus and platelet
glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina
or non Q wave myocardial infarction. Angiographic results from the PRISM─PLUS
trial. PRISM-PLUS Investigators. Circulation 1999;100(15):1609-15.
31) Cannon CP, et al. Oral glycoprotein IIb/IIIa inhibition
with orbofiban in patients with unstable coronary syndromes (OPUS─TIMI
16) trial. Circulation 2000;102(2):149-56.
32) Comparison of sibrafiban with aspirin for prevention
of cardiovascular events after acute coronary syndrome :a randomized
trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield
Maximum Protection from Ischemic Heart Events Post acute Coronary Syndromes.
Lancet 2000;355(9201):337-45.
33) Topol EJ, et al. Reduction of clinical restenosis
following coronary intervention with early administration of platelet
IIb/IIIa integrin blocking antibody;a randomized ,placebo controlled
,multi center trial. Lancet 1994;343:881-8.
34) The EPILOG Investigators. Platelet glycoprotein
IIb/IIIa receptor blockade and low dose heparin during percutaneous
coronary revascularization. N Engl J Med 1997;336:1689-96.
35) The EPISTENT Investigators.randomized placebo controlled
and balloon angioplasty controlled trial to assess safety of coronary
stenting with use of platelet glycoprotein IIb/IIIa blockade.Evaluation
of Platelet IIb/IIIa Inhibitor for Stenting.Lancet 1998;352(9122):87-92.
36) The IMPACT-II Investigators.randomized placebo controlled
trial of effect of eptifibatide on complications of percutaneous coronary
intervention :IMPACT─II.Lancet 1997;349:1422-8.
37) The RESTORE Investigators.Effect of platelet glycoprotein
IIb/IIIa blockade with tirofiban on adverse cardiac events in patients
with unstable angina for acute myocardial infarction. Circulation 1997;96:1445-53.
38) The Persantine Aspirin Reinfarction Study Research
Group.Persantin and aspirin in coronary heart disease. Circulation 1980;62:449-61.
39) Klimt CR, et al. Persantine Aspirin Reinfarction
Study PartII. Secondary coronary prevention with persantine and aspirin.
J Am Coll Cariol 1986;7:251-69.
40) Anti platelet Trialists' Collaboration.Secandary
prevention of vascular disease by prolonged antiplatelet treatment.Br
Med J 1988;296:32-331.
41) Anti-platelet Trialists' Collaboration.Collaborative
overview of randomized trials of antiplatelet therapy. Prevention of
death, myocardial infarction and stroke by prolonged antiplatelet therapy
in various categories of patients.Br Med J 1994;308:81-106.
42) Double blind trial of aspirin in primary prevention
of myocardial infarction in patients with stable chronic angina pectoris.
Lancet 1992;340:1421-5.
43) Leon MB,et al. A clinical trial comparing three
antithrombotic drug regimens after coronary artery stenting. N Engl
J Med 1998; 339(23):1665-71.
44) Dangas G,et al. Combination therapy with aspirin
plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute
thrombosis after successful native coronary stenting. Am J Cardiol 2001;87:470-2.
45) Taniuchi M, et al. Randomized comparison of ticlopidine
and clopidogrel after intracoronary stent implantation in a broad patient
population. Circulation 2001;104:539-43.
46) Estacio RO, et al. The effect of nisoldipine as
compared with enalapril on cardiovascular outcome in patients with non
insulin dependent diabetes and hypertension. N Engl J Med 1998;338:645-52.
47) Tatti P, et al. Outcome results of the Fosinopril
versus Amlodipine Cardiovascular Events randomized Trial in patients
with hypertension and NIDDM. Diabetes Care 1998;21:597-603.
48) HOPE Study Investigators.Effects of an angiotensin
converting enzyme inhibitor, ramipril on cardiovascular events in high
risk patients. N Engl J Med 2000;342:145-53.
49) ACE Inhibitor Myocardial Infarction Collaborative
Group.Indication for ACE inhibitors in the early treatment of acute
myocardial infarction. systematic overview of individual data from 100,000
patients in randomized trials. Circulation 1998;97:2202-12.
50) Domanski MJ, et al. Effect of angiotensin converting
enzyme inhibition on sudden cardiac death in patients following acute
myocardial infarction. J Am Coll Cardiol 1999;33:598-604.
51) ACE Inhibitor Myocardial Infarction Collaborative
Group: long Term ACE inhibitor therapy in patients with heart failure
or left ventricular dysfunction: a systematic overview of data from
individual patients. Lancet 2000;355:1575-81.
52) GB John Mancini, et al. Angiotensin converting enzyme
inhibition with quinapril improves endothelial vasomotor dysfunction
in patients with coronary artery disease. Circulation 1996;94:258-65.
53) Cashin Hemphill L, et al. Angiotensin converting
enzyme inhibition as antiatherosclerotic therapy: no answer yet. QUIET
investigators. Quinapril Ischemic Event Trial. Am J Cardiol 1999;83:43-7.
54) Dickstein K, et al. Comparison of the effects of
losartan and captopril on mortality in patients after acute myocardial
infarction: the OPTIMAAL trial design. Optimal Therapy in Myocardial
Infarction with the Angiotensin IIAntagonist Losartan. Am J Cardiol
1999 Feb 15;83:477-81.
55) Pfeffer M. Valsartan: improving outcome for patients
following acute myocardial infarction ? The VALIANT trial. Need for
superior management of hypertension with the goal of prolonging patients
life. A satellite symposium for 2nd international Symposium on Angiotensin
IIAntagonism. London, Februaly 16.1999.p4-5.
56) β Blocker Heart Attack Trial Research Group. A randomized
trial of propranonol in patients with acute myocardial infarction. JAMA
1982;247:1707-14.
57) Yusuf S, et al. Beta blocker during and after myocardial
infarction: an overview of the randomized trials. Prog Cardivasc Dis
1985;27:335-71.
58) Jonas M, et al. Usefulness of beta blocker therapy
in patients with non insulin dependent diabetes mellitus and coronary
artery disease. Am J Cardiol 1996;77:1273-7.
59) The Danish Study Group on Verapamil in Myocardial
Infarction: secondary prevention with verapamil after myocardial infarction.
Am J Cardiol 1990;66:33I-44I.
60) Held PH, et al. Calcium channel blockers acute myocardial
infarction and unstable angina: an overview. Br Med J 1989;299:1187-92.
61) Furberg CD, et al. Nifedipine, dose related increase
in mortality in patients with coronary heart disease. Circulation 1995;92:1326-31.
62) Multicenter Diltiazem Postinfarction Trial Research
Group. The effect of diltiazem on mortality and reinfarction after myocardial
infarction. N Engl J Med 1988;319:385-92.
63) John E, et al. Amlodipine reduces transient myocardial
ischemia in patients with coronary artery disease: double blind Circadian
Anti Ischemia Program in Europe. J Am Coll Cardiol 1994;24:1460-67.
64) Gruppo Italiano per lo Studio della Sopravvivenza
nell'Infarto Miocardico; GISSI03.effects of lisonopril and transdermal
glyceryl trinitrate singly and together on 6 weeks mortality and ventricular
function after acute myocardial infarction.Lancet 1994;343:1115-22.
65) ISIS−4 Collaborative Group.ISIS−4. A randomized
factorial trial assessing early oral captoril,oral mononitrate, and
magnessium sulphate in 58050 patients with suspected acute myocardial
infarction.Lancet 1995;345:669-85.
66) 石川欣司ほか.抗血小板薬，抗狭心症薬の心筋梗塞再発予防効果.心臓1993;25:637-44.
67) 中村保幸ほか.心筋梗塞と硝酸薬.Excerpta Medica 1999;p167-78.